CRISPR Loss-of-Function Screen Identifies the Hippo Signaling Pathway as the Mediator of Regorafenib Efficacy in Hepatocellular Carcinoma

Regorafenib is used for hepatocellular carcinoma (HCC), but its response does not last long, partly due to chemoresistance acquisition. We performed a clustered regularly interspaced short palindromic repeats (CRISPR)-based loss-of-function genetic screen and aimed to discover molecules involved in...

Descripción completa

Detalles Bibliográficos
Autores principales: Suemura, Shigeki, Kodama, Takahiro, Myojin, Yuta, Yamada, Ryoko, Shigekawa, Minoru, Hikita, Hayato, Sakamori, Ryotaro, Tatsumi, Tomohide, Takehara, Tetsuo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2019
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6770429/
https://www.ncbi.nlm.nih.gov/pubmed/31540262
http://dx.doi.org/10.3390/cancers11091362

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6770429/
https://www.ncbi.nlm.nih.gov/pubmed/31540262
http://dx.doi.org/10.3390/cancers11091362

Ejemplares similares